Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04382131
Other study ID # AC20042
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 23, 2020
Est. completion date October 31, 2020

Study information

Verified date July 2020
Source University of Edinburgh
Contact Aziz Sheikh
Phone 01316514151
Email aziz.sheikh@ed.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected or confirmed COVID-19 being managed at home.


Description:

COVID-19, a recently identified disease, has spread worldwide rapidly and is now a pandemic. There is no cure for it yet. Though it causes mild to moderate illness in most people, it can cause serious illness and death, particularly in the elderly, those with chronic illness or a weakened immune system.

The ELVIS COVID-19 study is to find out if nasal washout (i.e. irrigation) and gargling with salt water (hypertonic saline) helps individuals with COVID-19 get better faster. Preliminary data from those with the common cold has found that nasal washouts and gargling with salty water may be helpful in reducing the length of the illness. This trial will help us find out if the same treatment is helpful in improving COVID-19 symptoms and preventing the spread of the disease.

After self-consenting online, participants will be randomised into one of two study groups. The control group will be given standard personal, household hygiene and social distancing advice. The intervention group will be taught using online videos how to prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) up to 12 times daily in addition to standard advice.

Participants in both the intervention and control groups will complete an online daily diary first thing in the morning, which will be sent to them via an email link. The diaries will be completed every day until the participant reports they are well or for a maximum of 14 days or participant withdrawal.This study will look for participants across Scotland, who are 18 years old or older and who are self-isolating with confirmed or suspected COVID-19, with symptoms that have developed no more than 48 hours before consent to the study. The study is conducted online and everything we ask participants to do will be done at home with items they will already have.


Recruitment information / eligibility

Status Recruiting
Enrollment 405
Est. completion date October 31, 2020
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults (=18 years)

- Those living within the UK

- Those self-isolating at home within 48 hours of the start of the illness with:

1. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the following symptoms: recent onset of (i) new continuous cough and/or (ii) high temperature) and/or (iii) loss of, or change in, sense of smell or taste (anosmia) OR

2. Those with virologically confirmed SARS-CoV-2 infection and clinical symptoms indicative of COVID-19 (as detailed in (a) above).

- Provision of informed consent

Exclusion Criteria:

- Onset of illness>48 hours

- Inability to consent

- Pregnancy

- Immunosuppression

- Inability to perform HSNIG

- Those taking part in another interventional medical trial

- Those without access to a supply of salt

- Those who have had a negative COVID-19 swab result for the present symptoms

- Those with suspected/confirmed COVID-19 in whom hospital admission is recommended

- Those who do not have access to email/internet

- Those living in a household with another person currently participating in this study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
NaCl Solution
NaCl Solution prepared by participants at home using water and salt

Locations

Country Name City State
United Kingdom NHS Lothian Edinburgh

Sponsors (1)

Lead Sponsor Collaborator
University of Edinburgh

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to resolution of symptoms as defined by the single question 'how unwell do you feel today'. Time until participant reports well Maximum of 14 days
Secondary Severity of all symptoms Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe) 1-14 days or until the participant reports that they are well
Secondary The length of time for individual symptoms to resolve Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe) 1-14 days or until the participant reports that they are well
Secondary Severity of individual symptoms Recorded using validated Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) questionnaire and daily diaries. The WURSS-24 questionnaire assesses the interference on daily life and severity of symptoms on a scale of 1 (not at all) to 7 (severe) 1-14 days or until the participant reports that they are well
Secondary Contacting healthcare (NHS 24, OOH, GP) Number of participants and frequency of contacts 1-14 days or until the participant reports that they are well
Secondary Participants needing GP appointments Number of participants and frequency of contacts 1-14 days or until the participant reports that they are well
Secondary Participants attending hospital Number of participants 1-14 days or until the participant reports that they are well
Secondary Length of stay in hospital if admitted Number of days 1-14 days or until the participant reports that they are well
Secondary Number of participants reporting over the counter medication use Number of participants 1-14 days or until the participant reports that they are well
Secondary Reduction in transmission to household contacts Number of people within participant's household who develop symptoms 1-14 days or until the participant reports that they are well
Secondary Number of participants reporting side effects of nasal irrigation Number of participants in intervention arm reporting side effects 1-14 days or until the participant reports that they are well
Secondary Types and severity of side effects reported Participants asked if they have experienced common side effects or other and to rate the severity on a 7 point scale of 'Did not have this side effect' to 'severe' 1-14 days or until the participant reports that they are well
Secondary Cost of over the counter medication used Estimated cost requested when participant states over the counter medication used 1-14 days or until the participant reports that they are well
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2